Effect of Docosahexaenoic Acid Supplementation on neonatal outcomes of pereterm infants

INTERVENTION: Intervention group:Premature babies are divided into intervention and placebo groups using a random number table. So that the people who met the conditions to enter the study will be treated by pre‐coded pharmaceutical and placebo products prepared by the clinical pharmacist and the doctor and nurse of the ward have no knowledge of their original nature. The baby receives 60 cc/kg of milk enterally, starting and continuing for 14 days. If the baby is discharged from the ward earlier than 14 days, it will be excluded from the study. In both the intervention and control groups, available emulsions (including placebo and DHA) based on the weight of the baby with a dose of 0.5 cc/kg/day (as daily or every twelve hours based on the baby's tolerance) will be prescribed. During the daily visit, the request for the implementation of the intervention for 14 days will be included in the doctor's request sheet by the neonatologist. It will be given to the baby before feeding with breast milk and through gavage. It should be mentioned that DHA and placebo emulsion are similar in terms of color, volume and taste. Then, the growth indicators during the intervention period are daily and after completion. He will be evaluated weekly until he is discharged from the hospital and also after discharge in follow‐up clinics on a monthly basis, and the relevant checklists will be completed.More about this source textSource text required for additional translation informationSend feedbackSide panels. CONDITION: Nutrition of premature babies / Growth of premature babies / Prognosis of premature babies. PRIMARY OUTCOME: Determining the effect of Docosahexaenoic acid on the growth indices of premature infants. Timepoint: During the study, the growth indices will be checked daily to measure weight and weekly to measure height and head circumference, and they will be checked until the time the baby is admitted to the hospital. Method of measurement: A scale will be used to measure weight and a meter will be used to measure height. INCLUSION CRITERIA: Preterm infants with gestational age less than 34 weeks. Birth weight less than 2000 gr. SECONDARY OUTCOME: Investigating the effect of Docosahexaenoic acid acid acids on the incidence of neonatal sepsis in preterm infants. Timepoint: During the whole time of the baby's stay in the hospital. Method of measurement: Clinical finding and blood culture examination. Investigating the effect of Docosahexaenoic acid on the incidence of intraventricular hemorrhage in preterm infants. Timepoint: During the whole time of the baby's stay in the hospital. Method of measurement: With brain ultrasonography. Investigating the effect of Docosahexaenoic acids on the incidence of neonatal necrotizing enteroculitis in preterm infants. Timepoint: During the whole time of the baby's stay in the hospital. Method of measurement: clinical and radiological findings. Investigating the effect of Docosahexaenoic acids on the incidence of retinopathy of prematurity in preterm infants. Timepoint: During the whole time of the baby's stay in the hospital. Method of measurement: Based on the retinal exam by ophthalmologist.